Do natriuretic peptides have a new chance in treatment of heart failure?

Czech version

Authors: Lenka Špinarová ¹; Jindřich Špinar ²; Jiří Vítovec ¹
Authors‘ workplace: I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, Ph. D., FESC ¹; Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ²
Published in: Vnitř Lék 2014; 60(12): 1076-1080
Category: 70. birthday prof. MUDr. Michael Aschermann, DrSc., FESC, FACC

Overview

The effect of natriuretic peptides on cardiovascular and renal system offers a potential benefit in therapy of hypertension and heart failure; however the current results of clinical trials are not encouraging. Synthetic B natriuretic peptide has demonstrated short-term hemodynamic improvement in patients, but in terms of renal function and long-term prognosis the effect was questionable. Nevertheless, new hope is ularitid a dual inhibitor of neprilysin and ARB: LCZ 696, the ongoing clinical studies and previous data from pilot studies appear promising.

Key words:
heart failure – natriuretic peptides – vasopeptidase inhibitors

Sources

1. Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. A randomized, double-blind, placebo-controlled clinical trial. NATRECOR Study Group. J Am Coll Cardiol 1999; 34(1): 155–162.

2. Colluci WS, Elkayem U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. NESIRITIDE Study Group. N Engl J Med 2000; 343(4): 246–253. Errata in N Engl J Med 2000 Nov 16; 343(20): 1504 et N Engl J Med 2000; 343(12): 896.

3. The VMAC Investigators. Intravenous neseritide vs nitroglycerin for treatment of decompesated congestive heart failure. JAMA 2002; 287(12): 1531–1540. Erratum in JAMA 2002; 288(5): 577.

4. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111(12): 1487–1491. Erratum in Circulation 2005; 111(17): 2274.

5. O´Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1): 32–43. Erratum in N Engl J Med. 2011; 365(8): 773.

6. Chen HH, Anstrom KJ, Givertz MM et al. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. The ROSE Acute Heart Failure Randomized Trial. JAMA 2013; 310(23): 2533–2543.

7. Mitrovic V, Seferovic PM, Simeunovic D et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27(23): 2823–2832.

8. Clinicaltrials.gov. Dostupné z WWW: <http://www.clinicaltrials.gov/ct2/show/NCT01035255>.

9. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103–111.

10. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920–926.

11. Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual acting angiotensin receptor – neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50(4): 401–414.

12. Salomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 308(9851): 1387–1395.

13. McMurray JJ, Packer M, Desai AS et al. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15(9): 1062–1073.